Fed. Circ. Focuses On Breadth Of UPenn IP In Eligibility Fight

The University of Pennsylvania and Regenxbio Inc. on Tuesday tried to persuade a Federal Circuit panel that their gene therapy patent should be revived, but at least one judge repeatedly said...

Already a subscriber? Click here to view full article